Compare PATH & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PATH | ABVX |
|---|---|---|
| Founded | 2005 | 2013 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.9B | 9.0B |
| IPO Year | 2021 | N/A |
| Metric | PATH | ABVX |
|---|---|---|
| Price | $16.49 | $132.11 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 15 | 12 |
| Target Price | $15.50 | ★ $115.83 |
| AVG Volume (30 Days) | ★ 27.5M | 1.8M |
| Earning Date | 12-03-2025 | 08-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.42 | N/A |
| Revenue | ★ $1,553,111,000.00 | $6,231,374.00 |
| Revenue This Year | $13.59 | $6.80 |
| Revenue Next Year | $9.61 | N/A |
| P/E Ratio | $39.65 | ★ N/A |
| Revenue Growth | ★ 10.05 | N/A |
| 52 Week Low | $9.38 | $4.77 |
| 52 Week High | $19.84 | $148.83 |
| Indicator | PATH | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 52.33 | 56.07 |
| Support Level | $16.33 | $139.42 |
| Resistance Level | $17.36 | $147.00 |
| Average True Range (ATR) | 0.74 | 7.10 |
| MACD | -0.10 | 0.88 |
| Stochastic Oscillator | 25.83 | 59.52 |
UiPath Inc offers an end-to-end cross-application enterprise automation platform principally with computer vision technology and user interface automations in its initial RPA offering, which remains the foundation of the platform. The platform leverages a range of automation technologies including robotic process automation, application programming interface, and artificial intelligence. UiPath's solution can automate a broad range of repetitive tasks across industries including claims processing, employee onboarding, invoice to cash, loan applications, and customer service.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.